

Fig. 1










Fig. 3







25 26 27 28 29 30 31 32 33 34 35 36

10sec

16K 🗪

Fig. 5





Fig. 6






Fig. 7




Fig. 8





Fig. 9



I

G

z

SNS

AKDVLFAIKEVGFRG

S

EHPKIEFY

ഗ

Ø

G

8 9 0

4 5 6

789012

200

0 တ PPTGKRL ω LPGR 6 7 8 137-151 (anti p63/44 antibody) (anti LCCL antibody) FTRGLDIRKEKA G Ŋ Ŋ LQKNFVGKVALM 4 S GPVRVY H 9012 2345678901 STQEATGQAVST 36 - 50S 9 ⇒p44 വ z VISI 23 0 1 2 SEGAAPIAI R F N 9 0 1 0 <u>ح</u> 67890 O ن SVYGNIVYASVSSICGAAVH œ ω တ Ø 5678901234567 34567 SVDANGIQSQMLSRWSASFTVTKGK 45678901234567 KDCKADIAFLIDGSFNIG (anti p63/44/40 antibody) (anti LCCL 3 antibody) 63-83 (anti LCCL 1 antibody) G CLLLLPGPA 56789012 114-127 63-181 <u>></u> က 3456789012 (anti LCCL 2 antibody) z တ G ω KIPEKK 345 SA G G 100 100 150 20 0

10/10